Press Releases 2018

The protocol for the Phase 3 clinical trial will be designed to meet expectations from both the U.S and EU regulatory agencies.

This includes a significant reduction in the Corporation’s cash use in 2019, driven by significant growth in its bioseparation revenues & a reduction of anticipated R&D expenditures by up to $30m.

Implementation of cost control measures to significantly reduce operational burn and extend cash runway

Maturity Dates of the Line of Credit and Long-Term (OID) Loans extended to September 2024

Prometic announced today that it will report its financial results for the third quarter ended September 30, 2018 on Wednesday November 14, 2018 after market close.

As a result of the extension, the maturity dates of the Debt will be amended to September 2024, requiring no repayment of the sums borrowed until then.

This initiative, sponsored by Prometic, aims to raise awareness and improve understanding of this rare disease and its effects. Plasminogen Deficiency Awareness Week is a free 4-day online event

Implementation plan for additional analytical assays and in-process controls confirmed and PLI finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing

Key Opinion Leader meeting, Friday, September 7th in New York City, on a novel treatment for Alström Syndrome (AS).

Prometic has advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).

n the ongoing Phase 2 clinical trial in patients with Alström syndrome, PBI-4050 was shown to significantly reduce liver and cardiac fibrosis.

Prometic announced today that it will report its financial results for the second quarter ended June 30, 2018 on Tuesday August 14, 2018 after market close.

In addition to the Rare Pediatric Disease Designation, PBI-4050 was previously granted Orphan Drug Designation by the FDA and the EMA for the treatments of AS and idiopathic pulmonary fibrosis (IPF).

Prometic it will hold a conference call on Wednesday June 27, 2018 to report on its progress in implementing the updated corporate plan presented during its AGM on Wednesday May 9th 2018.

New data suggest PBI-4547 offers potential as novel therapy for liver fibrosis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), diabetes and obesity.

Treatment with PBI-4050 for 12 weeks positively affected biomarkers known to have antifibrotic activity

Clinical programs streamlined to manage costs for balance of 2018 and continued positive clinical activity demonstrated by PBI-4050 to catalyze partnership discussions

Prometic continued in 2017 its transition that has transformed the company into a biopharmaceutical company with two drug discovery platforms focusing on rare and orphan diseases.

Prometic’s IVIG demonstrated comparable safety and efficacy data to existing commercial IVIG products without any significant drug related safety issues.